AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09926 AKESO

Market Closed 02-20 16:08:38

109.100

+3.900

+3.71%

High110.900	Low103.500	Vol2.57M
Open105.200	D1 Closing105.200	Amplitude7.03%
Mkt Cap100.48B	Tradable Cap100.48B	Total Shares921.00M
T/O280.40M	T/O Rate0.28%	Tradable Shares921.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"AKESO","latestPrice":109.1,"timestamp":1771574918009,"preClose":105.2,"halted":0,"volume":2570996,"delay":0,"changeRate":0.037072243346007526,"floatShares":921000000,"shares":921000000,"eps":-0.604581,"marketStatus":"Market Closed","change":3.9,"latestTime":"02-20 16:08:38","open":105.2,"high":110.9,"low":103.5,"amount":280402976,"amplitude":0.070342,"askPrice":109.3,"askSize":3000,"bidPrice":109.1,"bidSize":18000,"shortable":3,"etf":0,"ttmEps":-1.007,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771810200000},"marketStatusCode":7,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":105.2,"openAndCloseTimeList":[[1771551000000,1771560000000],[1771563600000,1771574400000]],"volumeRatio":0.7505667807357329,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.7053,"impliedVolPercentile":0.9545},"requestUrl":"/m/hq/s/09926/tweets","defaultTab":"tweets","newsList":[{"id":"2611120049","title":"Assessing Akeso (SEHK:9926) Valuation After AK139 Trial Approval And Ivonescimab Breakthrough Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2611120049","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611120049?lang=en_us&edition=fundamental","pubTime":"2026-02-15 23:23","pubTimestamp":1771168997,"startTime":"0","endTime":"0","summary":"Akeso (SEHK:9926) has just received approval in China to start Phase II trials for AK139, a first in class IL-4Ra/ST2 bispecific antibody, targeting seven respiratory and autoimmune conditions.\nSee our latest analysis for Akeso.\nInvestors seem to be weighing Akeso's busy clinical calendar against recent volatility, with a 1 day share price return of 1.54% and 7 day return of 4.36% following the AK139 and ivonescimab updates. The 1 year total shareholder return of 74.92% points to strong...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/assessing-akeso-sehk9926-valuation-after-ak139-trial-approva","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/assessing-akeso-sehk9926-valuation-after-ak139-trial-approva","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0348767384.USD","LU0634319403.HKD","LU0348766576.USD","LU2476274308.USD","LU2476274720.SGD","LU1720050803.USD","LU1961090484.USD","LU0417516571.SGD","LU1794554557.SGD","LU0417516902.SGD","IE00BPRC5H50.USD","LU2399975544.HKD","LU0348783233.USD","LU0540923850.HKD","LU0348735423.USD","LU0561508036.HKD","BK1161","LU0417516738.SGD","IE00B5MMRT66.SGD","LU0348827113.USD","BK1574","LU2778985437.USD","LU0348825331.USD","LU0348784397.USD","IE00B543WZ88.USD","09926","LU2488822045.USD"],"gpt_icon":0},{"id":"2610598760","title":"Akeso Receives Chinese Approval to Begin Phase II Trials of IL-4Rα/ST2 Bispecific Antibody Across Seven Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2610598760","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610598760?lang=en_us&edition=fundamental","pubTime":"2026-02-11 17:02","pubTimestamp":1770800555,"startTime":"0","endTime":"0","summary":"Akeso Inc. has received approval from the National Medical Products Administration to initiate Phase II clinical trials for its bispecific antibody AK139 in China. The trials will cover seven indications, including chronic obstructive pulmonary disease , severe bronchial asthma, chronic spontaneous urticaria, allergic rhinitis, chronic rhinosinusitis with nasal polyps, moderate-to-severe atopic dermatitis, and prurigo nodularis. AK139 is the first clinical-stage antibody to target both IL-4Rα and ST2 pathways, and the Phase II studies aim to evaluate its therapeutic potential in respiratory and autoimmune diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL8jL4rt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0348767384.USD","LU2476274720.SGD","BK1574","IE00B5MMRT66.SGD","LU0348783233.USD","LU0417516902.SGD","LU1794554557.SGD","LU2488822045.USD","09926","LU0348766576.USD","LU1720050803.USD","LU0348825331.USD","LU0348827113.USD","LU0417516738.SGD","LU0561508036.HKD","IE00B543WZ88.USD","LU1961090484.USD","LU0348784397.USD","IE00BPRC5H50.USD","LU2476274308.USD","LU0634319403.HKD","LU0417516571.SGD","LU0348735423.USD","LU0540923850.HKD","LU2399975544.HKD","LU2778985437.USD"],"gpt_icon":0},{"id":"2609653238","title":"Akeso Reports Promising Phase III Results for Ivonescimab in Advanced Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2609653238","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609653238?lang=en_us&edition=fundamental","pubTime":"2026-02-06 10:27","pubTimestamp":1770344844,"startTime":"0","endTime":"0","summary":"Akeso Inc. has announced that its bispecific antibody ivonescimab has received its fifth Breakthrough Therapy Designation from the National Medical Products Administration  of China for use in combination with chemotherapy as a first-line treatment for advanced biliary tract cancer . This designation follows previous recognitions for indications in lung cancer and triple-negative breast cancer. A randomized, controlled, multicenter Phase III clinical study  is currently underway, comparing ivonescimab plus chemotherapy to durvalumab plus chemotherapy for first-line treatment of advanced BTC. Patient enrollment for this trial has been completed. Results from a Phase 1b/II study were presented at the 2024 American Society of Clinical Oncology  Annual Meeting, showing an objective response rate of 63.6% and a disease control rate of 100% for ivonescimab plus chemotherapy. The regimen also demonstrated a median progression-free survival of 8.5 months and a median overall survival of 16.8 m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL3MwHJr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","LU1961090484.USD","LU0348767384.USD","LU2488822045.USD","BK1574","LU0348766576.USD","09926","LU0540923850.HKD","LU0417516738.SGD","LU1794554557.SGD","LU1720050803.USD","BK1161","LU0348784397.USD","LU0348825331.USD","LU2778985437.USD","LU0348735423.USD","LU0417516571.SGD","LU2399975544.HKD","LU2476274308.USD","IE00B5MMRT66.SGD","LU0561508036.HKD","IE00B543WZ88.USD","LU0634319403.HKD","LU0417516902.SGD","LU2476274720.SGD","LU0348783233.USD","IE00BPRC5H50.USD"],"gpt_icon":0},{"id":"2609323885","title":"Akeso startet Phase-III-Studie mit Ivonescimab zur Erstlinienbehandlung von fortgeschrittenem Gallengangskrebs","url":"https://stock-news.laohu8.com/highlight/detail?id=2609323885","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609323885?lang=en_us&edition=fundamental","pubTime":"2026-02-06 10:27","pubTimestamp":1770344844,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire  on February 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL5KgrXt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720050803.USD","LU2476274308.USD","IE00B5MMRT66.SGD","LU0348784397.USD","LU0561508036.HKD","BK1574","IE00BPRC5H50.USD","LU0348825331.USD","LU1794554557.SGD","LU0348783233.USD","09926","LU0417516571.SGD","LU0634319403.HKD","LU2778985437.USD","LU1961090484.USD","BK1161","IE00B543WZ88.USD","LU0417516902.SGD","LU0417516738.SGD","LU2488822045.USD","LU2476274720.SGD","LU0348735423.USD","LU0540923850.HKD","LU0348827113.USD","LU2399975544.HKD","LU0348766576.USD","LU0348767384.USD"],"gpt_icon":0},{"id":"1166485515","title":"Akeso, Inc. (09926) Announces Monthly Return for January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1166485515","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166485515?lang=en_us&edition=fundamental","pubTime":"2026-02-05 17:34","pubTimestamp":1770284062,"startTime":"0","endTime":"0","summary":"Akeso, Inc. (09926) reported no changes in its authorized share capital for January 2026, holding at 5,000,000,000 ordinary shares with a total par value of USD 50,000. The number of issued shares...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"gpt_icon":0},{"id":"2608870683","title":"BRIEF-Akeso Granted Exclusive Commercialization Rights For Ebronucimab Injection To Jumpcan Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2608870683","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608870683?lang=en_us&edition=fundamental","pubTime":"2026-02-03 22:55","pubTimestamp":1770130536,"startTime":"0","endTime":"0","summary":"BRIEF-Akeso Granted Exclusive Commercialization Rights For Ebronucimab Injection To Jumpcan PharmaceuticalFeb 3  - Akeso Inc 9926.HK:AKESO GRANTED EXCLUSIVE COMMERCIALIZATION RIGHTS FOR EBRONUCIMAB INJECTION TO JUMPCAN PHARMACEUTICALTO RECEIVE RMB80 MILLION LICENSE FEE AND RMB10 MILLION MILESTONESFurther company coverage: 9926.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YZ0D9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348735423.USD","LU0348825331.USD","LU0417516571.SGD","LU1720050803.USD","LU0348827113.USD","LU0348766576.USD","IE00B5MMRT66.SGD","LU0561508036.HKD","LU0348784397.USD","IE00BPRC5H50.USD","LU2778985437.USD","LU0417516738.SGD","09926","LU0348783233.USD","LU2488822045.USD","LU1961090484.USD","LU2476274308.USD","BK1161","LU2476274720.SGD","IE00B543WZ88.USD","LU2399975544.HKD","LU0417516902.SGD","LU0634319403.HKD","LU0540923850.HKD","BK1574","LU1794554557.SGD","LU0348767384.USD"],"gpt_icon":0},{"id":"2608187904","title":"Akeso Grants Commercialization Rights for Hypercholesterolemia Drug to Hubei Jumpcan Pharmaceutical Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2608187904","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608187904?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:17","pubTimestamp":1770124673,"startTime":"0","endTime":"0","summary":"Akeso (HKG:9926) units Akeso Biopharma and AD Pharmaceuticals granted JumpCan Pharmaceutical exclusive commercialization rights for the ebronucimab injection within China, according to a Tuesday Hong ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1720050803.USD","BK0201","BK0012","LU2476274308.USD","IE00B5MMRT66.SGD","LU0348784397.USD","LU0561508036.HKD","BK0188","BK1574","IE00BPRC5H50.USD","LU0348825331.USD","LU1794554557.SGD","BK0239","LU0348783233.USD","09926","LU0417516571.SGD","BK0187","600566","LU0634319403.HKD","LU2778985437.USD","LU1961090484.USD","BK1161","BK0077","IE00B543WZ88.USD","LU0417516902.SGD","LU0417516738.SGD","LU2488822045.USD","LU2476274720.SGD","LU0348735423.USD","LU0540923850.HKD","LU0348827113.USD","BK0028","LU2399975544.HKD","LU0348766576.USD","LU0348767384.USD"],"gpt_icon":0},{"id":"1172082434","title":"Akeso (9926) and JumpCan (600566.SS) Sign Exclusive Commercialization Agreement for 伊喜寧®","url":"https://stock-news.laohu8.com/highlight/detail?id=1172082434","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172082434?lang=en_us&edition=fundamental","pubTime":"2026-02-03 19:23","pubTimestamp":1770117810,"startTime":"0","endTime":"0","summary":"Akeso, Inc. (9926) has entered into an agreement with JumpCan Pharmaceutical Group Co., Ltd. and Jiangsu Jiyuan Pharmaceutical Co., Ltd., both wholly owned subsidiaries of Hubei JumpCan...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"gpt_icon":0},{"id":"1165430493","title":"AKESO (09926) Grants Exclusive Commercialization Rights for Yixining® to Jumpcan Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=1165430493","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165430493?lang=en_us&edition=fundamental","pubTime":"2026-02-03 19:16","pubTimestamp":1770117392,"startTime":"0","endTime":"0","summary":"AKESO (09926) announced that its indirect wholly-owned subsidiaries, Zhongshan Akeso Biopharma Co., Ltd. and Kangrong Oriental (Guangdong) Pharmaceutical Co., Ltd. (collectively referred to as...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2476274308.USD","LU1794554557.SGD","BK0239","LU0348767384.USD","LU0348766576.USD","BK0187","BK0201","LU2778985437.USD","LU2399975544.HKD","BK0188","IE00B543WZ88.USD","BK0077","BK1161","LU0348825331.USD","BK0012","LU2488822045.USD","LU1720050803.USD","09926","BK1574","LU2476274720.SGD","BK0028","LU0348827113.USD","600566","LU0417516738.SGD","LU0561508036.HKD","LU0348735423.USD","LU0348784397.USD","IE00BPRC5H50.USD","LU0634319403.HKD","LU0348783233.USD","IE00B5MMRT66.SGD","LU0417516571.SGD","LU0540923850.HKD","LU1961090484.USD","LU0417516902.SGD"],"gpt_icon":0},{"id":"2608782708","title":"Akeso - Akeso Granted Exclusive Commercialization Rights for Ebronucimab Injection to Jumpcan Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2608782708","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608782708?lang=en_us&edition=fundamental","pubTime":"2026-02-03 19:08","pubTimestamp":1770116932,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YZ0D9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0348767384.USD","IE00B543WZ88.USD","LU0348735423.USD","LU2476274720.SGD","IE00B5MMRT66.SGD","LU2476274308.USD","BK1574","LU0348784397.USD","LU0417516738.SGD","LU0540923850.HKD","LU2778985437.USD","LU2399975544.HKD","LU0417516571.SGD","LU0348766576.USD","LU0634319403.HKD","09926","BK1161","LU1961090484.USD","LU0348825331.USD","IE00BPRC5H50.USD","LU0417516902.SGD","LU1720050803.USD","LU2488822045.USD","LU0561508036.HKD","LU0348827113.USD","LU0348783233.USD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2608382703","title":"Akeso - to Receive RMB80 Mln License Fee and RMB10 Mln Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2608382703","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608382703?lang=en_us&edition=fundamental","pubTime":"2026-02-03 19:08","pubTimestamp":1770116932,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YZ0D9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2476274720.SGD","LU1720050803.USD","LU0634319403.HKD","IE00B5MMRT66.SGD","LU0417516571.SGD","LU0348767384.USD","LU1961090484.USD","IE00B543WZ88.USD","LU2778985437.USD","LU0348784397.USD","LU1794554557.SGD","BK1574","LU0417516738.SGD","LU2399975544.HKD","LU0348783233.USD","LU0348766576.USD","BK1161","LU0561508036.HKD","LU0348827113.USD","LU2476274308.USD","LU0348735423.USD","LU0540923850.HKD","LU2488822045.USD","09926","IE00BPRC5H50.USD","LU0417516902.SGD","LU0348825331.USD"],"gpt_icon":0},{"id":"2606216424","title":"Akeso Updates Contract Manufacturing Arrangement with Supplemental Agreement Expiry Set for 2039","url":"https://stock-news.laohu8.com/highlight/detail?id=2606216424","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606216424?lang=en_us&edition=fundamental","pubTime":"2026-01-26 18:11","pubTimestamp":1769422310,"startTime":"0","endTime":"0","summary":"Akeso Inc. announced further information regarding its ongoing contract manufacturing arrangement involving CTTQ-Akeso, Akeso Biopharma, Chai Tai Tianqing, and Nanjing Tianqing. The company clarified that the term of the Supplemental Agreement is fixed until August 29, 2039, with the possibility for parties to enter into a new agreement upon expiry, subject to necessity, product sales performance, and prevailing circumstances. The annual procurement caps for monoclonal antibody  products under the agreement were determined by considering historical procurement amounts, anticipated market demand growth, and potential price or demand fluctuations. The procurement price will be based on actual manufacturing costs plus a reasonable profit margin, taking into account raw material costs, manufacturing scale, and profit margins of comparable publicly listed contract manufacturers, with adjustments for specific manufacturing processes.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL4nL5zQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348783233.USD","LU0348827113.USD","IE00B543WZ88.USD","LU0348767384.USD","LU0348784397.USD","LU1720050803.USD","IE00BPRC5H50.USD","LU2488822045.USD","BK1161","LU0417516571.SGD","LU0417516902.SGD","LU2476274720.SGD","LU0417516738.SGD","LU1794554557.SGD","BK1574","LU1961090484.USD","LU0348766576.USD","LU2476274308.USD","LU0348735423.USD","IE00B5MMRT66.SGD","LU2778985437.USD","LU0634319403.HKD","LU2399975544.HKD","LU0540923850.HKD","09926","LU0561508036.HKD","LU0348825331.USD"],"gpt_icon":0},{"id":"2605923955","title":"Gumokimab sNDA Acceptance for Ankylosing Spondylitis Could Be A Game Changer For Akeso (SEHK:9926)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605923955","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605923955?lang=en_us&edition=fundamental","pubTime":"2026-01-24 17:32","pubTimestamp":1769247139,"startTime":"0","endTime":"0","summary":"Earlier this month, Akeso announced that China’s National Medical Products Administration accepted its supplemental New Drug Application for gumokimab (AK111), an anti‑IL‑17A antibody for active ankylosing spondylitis, supported by positive Phase III data. \nThis milestone highlights Akeso’s expanding non‑oncology portfolio and the potential for gumokimab to address a large ankylosing spondylitis patient population in China. \nWe’ll now examine how gumokimab’s sNDA acceptance, supported by...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/gumokimab-snda-acceptance-for-ankylosing-spondylitis-could-b","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/gumokimab-snda-acceptance-for-ankylosing-spondylitis-could-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2476274720.SGD","LU0348783233.USD","LU0634319403.HKD","LU0348827113.USD","LU1720050803.USD","LU0348825331.USD","BK1574","09926","LU0348766576.USD","IE00B5MMRT66.SGD","LU1794554557.SGD","LU2488822045.USD","LU0348784397.USD","IE00B543WZ88.USD","BK1161","LU0417516571.SGD","LU2399975544.HKD","LU1961090484.USD","LU2476274308.USD","LU0561508036.HKD","LU0348767384.USD","LU0540923850.HKD","IE00BPRC5H50.USD","LU0417516902.SGD","LU2778985437.USD","LU0348735423.USD","LU0417516738.SGD"],"gpt_icon":0},{"id":"1142659698","title":"Hong Kong Stock Innovative Drug Concept Continues Rally, Akeso Surges Over 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142659698","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142659698?lang=en_us&edition=fundamental","pubTime":"2026-01-23 10:31","pubTimestamp":1769135501,"startTime":"0","endTime":"0","summary":"On January 23, the innovative drug concept in Hong Kong stocks continued its upward trajectory. Everest Medicines surged over 7%, while XtalPi Holdings and Akeso rose more than 4%. Kelun-Biotech...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0561508036.HKD","LU0417516902.SGD","LU0348783233.USD","LU0634319403.HKD","LU0417516571.SGD","02800","06978","IE00BPRC5H50.USD","LU2778985437.USD","LU0417516738.SGD","159992","LU2399975544.HKD","LU1720050803.USD","LU0348766576.USD","LU1961090484.USD","IE00B5MMRT66.SGD","LU0540923850.HKD","IE00B543WZ88.USD","LU2476274720.SGD","LU2488822045.USD","BK1574","LU0348827113.USD","LU0348735423.USD","LU0348767384.USD","LU1794554557.SGD","LU0348825331.USD","LU0348784397.USD","BK1610","LU2476274308.USD","09926"],"gpt_icon":1},{"id":"1116688046","title":"AKESO Surges Over 5% in Early Trading as Second Indication for Self-Developed Gumokimab Receives NDA Acceptance","url":"https://stock-news.laohu8.com/highlight/detail?id=1116688046","media":"Deep News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116688046?lang=en_us&edition=fundamental","pubTime":"2026-01-23 10:26","pubTimestamp":1769135178,"startTime":"0","endTime":"0","summary":"AKESO (09926) rose more than 5% in early trading. At the time of writing, the stock was up 5.25% to HK$118.30, with a turnover of HK$377 million. According to an announcement on AKESO's official...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B543WZ88.USD","IE00BPRC5H50.USD","LU0348767384.USD","BK1161","LU2778985437.USD","LU2476274308.USD","BK1574","LU0348735423.USD","LU1794554557.SGD","LU0348827113.USD","LU0417516571.SGD","LU2399975544.HKD","LU1961090484.USD","LU0348825331.USD","09926","LU0540923850.HKD","LU0348784397.USD","LU0348766576.USD","LU0417516738.SGD","IE00B5MMRT66.SGD","LU0348783233.USD","LU0561508036.HKD","LU2488822045.USD","LU0417516902.SGD","LU2476274720.SGD","LU1720050803.USD","LU0634319403.HKD"],"gpt_icon":0},{"id":"2605668469","title":"Akeso (SEHK:9926) Valuation Check After Recent Share Price Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=2605668469","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605668469?lang=en_us&edition=fundamental","pubTime":"2026-01-22 14:36","pubTimestamp":1769063769,"startTime":"0","endTime":"0","summary":"Why Akeso is on investors’ radars today\nAkeso (SEHK:9926) has attracted fresh attention after recent share price moves, with the stock showing a 1 day return of 3.1% decline and a 7 day return of 7.6% decline from its last close of HK$114. Investors are weighing these short term moves against its longer term record and the company’s current fundamentals.\nSee our latest analysis for Akeso.\nWhile the recent 1 day and 7 day share price returns are both in decline, Akeso’s 1 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-valuation-check-after-recent-share-price-pull","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-valuation-check-after-recent-share-price-pull","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2476274720.SGD","LU0348783233.USD","DCF","LU0634319403.HKD","LU0348827113.USD","LU1720050803.USD","LU0348825331.USD","BK1574","09926","LU0348766576.USD","IE00B5MMRT66.SGD","LU1794554557.SGD","LU2488822045.USD","LU0348784397.USD","IE00B543WZ88.USD","BK1161","LU0417516571.SGD","LU2399975544.HKD","LU1961090484.USD","LU2476274308.USD","LU0561508036.HKD","LU0348767384.USD","LU0540923850.HKD","IE00BPRC5H50.USD","LU0417516902.SGD","LU2778985437.USD","LU0348735423.USD","LU0417516738.SGD"],"gpt_icon":0},{"id":"2604138587","title":"Akeso sNDA for Gumokimab in Ankylosing Spondylitis Accepted for NMPA Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2604138587","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604138587?lang=en_us&edition=fundamental","pubTime":"2026-01-19 19:25","pubTimestamp":1768821905,"startTime":"0","endTime":"0","summary":"Akeso Inc. announced that the National Medical Products Administration  in China has accepted the supplemental New Drug Application  for gumokimab , a humanized anti-IL-17A monoclonal antibody, for the treatment of active ankylosing spondylitis. This marks the second indication for gumokimab to receive NDA review, following its earlier acceptance for moderate-to-severe psoriasis. The NDA acceptance is supported by positive results from a pivotal Phase III clinical trial, which demonstrated significant improvements in symptoms and quality of life for patients with active ankylosing spondylitis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire  on Ja","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nNDL9r8TQl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","LU0417516902.SGD","BK1161","LU2488822045.USD","LU0348825331.USD","LU0540923850.HKD","LU2476274308.USD","LU0561508036.HKD","LU0348766576.USD","IE00BPRC5H50.USD","LU0348735423.USD","IE00B5MMRT66.SGD","LU1794554557.SGD","IE00B543WZ88.USD","LU0417516571.SGD","LU2399975544.HKD","LU0417516738.SGD","09926","LU2778985437.USD","LU0348827113.USD","LU0348767384.USD","LU1720050803.USD","LU1961090484.USD","LU2476274720.SGD","LU0634319403.HKD","LU0348784397.USD","LU0348783233.USD"],"gpt_icon":0},{"id":"2604366138","title":"Akeso Announces Nmpa Acceptance of Second Nda for Gumokimab (Il-17a Inhibitor) in Active Ankylosing Spondylitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2604366138","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604366138?lang=en_us&edition=fundamental","pubTime":"2026-01-19 19:24","pubTimestamp":1768821890,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nTUA2XB9Z3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2476274720.SGD","09926","LU0348735423.USD","LU0540923850.HKD","IE00BPRC5H50.USD","LU0561508036.HKD","LU2399975544.HKD","LU1794554557.SGD","LU0348784397.USD","LU0348827113.USD","LU2488822045.USD","LU2476274308.USD","BK1161","LU0634319403.HKD","BK1574","LU1720050803.USD","LU2778985437.USD","LU0417516571.SGD","LU0348783233.USD","LU0417516738.SGD","IE00B543WZ88.USD","LU0348825331.USD","LU0348766576.USD","LU0348767384.USD","LU0417516902.SGD","IE00B5MMRT66.SGD","LU1961090484.USD"],"gpt_icon":0},{"id":"1168374108","title":"CICC Hong Kong Stock Connect and Hang Seng Index Adjustment Preview: Zijin Gold Intl (02259) Among Potential Hang Seng Index Additions; 44 Companies Expected to Enter Stock Connect","url":"https://stock-news.laohu8.com/highlight/detail?id=1168374108","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168374108?lang=en_us&edition=fundamental","pubTime":"2026-01-19 14:24","pubTimestamp":1768803841,"startTime":"0","endTime":"0","summary":"According to a research report from CICC, Hang Seng Indexes Company will announce the official results of the Hang Seng Index Series review after the market close on Friday, February 13, 2026, with...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XPEV","MCHmain","02833","LU0593848301.USD","HHImain","09987","HK0000252152.HKD","09868","SGXZ86797644.SGD","HK0000500386.USD","SGXZ62798434.SGD","LU2213484517.USD","06181","06160","688235","BK4614","HK0000252160.HKD","BK1198","ONC","601601","YUMC","02328","02601","09926","LU2543165471.USD","513600","02259"],"gpt_icon":1},{"id":"2603366565","title":"Akeso Reports Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2603366565","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603366565?lang=en_us&edition=fundamental","pubTime":"2026-01-14 11:54","pubTimestamp":1768362882,"startTime":"0","endTime":"0","summary":"Akeso Inc. has announced results from a real-world study comparing cadonilimab plus chemotherapy to a PD-1 inhibitor plus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction cancer with PD-L1 CPS <5. The findings, presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium , indicate that the cadonilimab regimen significantly improved both overall survival  and progression-free survival  compared to the PD-1 inhibitor group. The objective response rate was also higher in the cadonilimab group . Safety profiles were comparable between the two groups, with no significant difference in grade 3-4 adverse events. The full study has been accepted for publication in the Journal of Gastrointestinal Oncology. Akeso is also advancing prospective Phase III studies, including the COMPASSION-37 trial, which received FDA approval to initiate at the end of 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL6SDyTW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0348767384.USD","LU2476274720.SGD","BK1574","IE00B5MMRT66.SGD","LU0348783233.USD","LU0417516902.SGD","LU1794554557.SGD","LU2488822045.USD","09926","LU0348766576.USD","LU1720050803.USD","LU0348825331.USD","LU0348827113.USD","LU0417516738.SGD","LU0561508036.HKD","IE00B543WZ88.USD","LU1961090484.USD","LU0348784397.USD","IE00BPRC5H50.USD","LU2476274308.USD","LU0634319403.HKD","LU0417516571.SGD","LU0348735423.USD","LU0540923850.HKD","LU2399975544.HKD","LU2778985437.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":0.0361},{"period":"1month","weight":-0.043},{"period":"3month","weight":0.0196},{"period":"6month","weight":-0.3833},{"period":"1year","weight":0.702},{"period":"ytd","weight":-0.0345}],"compareEarnings":[{"period":"1week","weight":-0.0058},{"period":"1month","weight":-0.0065},{"period":"3month","weight":0.0473},{"period":"6month","weight":0.0424},{"period":"1year","weight":0.1699},{"period":"ytd","weight":0.0305}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.333333,"avgChangeRate":0.022352},{"month":3,"riseRate":0.4,"avgChangeRate":-0.035342},{"month":4,"riseRate":0.8,"avgChangeRate":0.041218},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.003133},{"month":6,"riseRate":0.666667,"avgChangeRate":0.133235},{"month":7,"riseRate":0.5,"avgChangeRate":0.087867},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007754},{"month":9,"riseRate":0.5,"avgChangeRate":0.036209},{"month":10,"riseRate":0.5,"avgChangeRate":0.046029},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"AKESO","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AKESO(09926) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AKESO,09926,AKESO股票,AKESO股票老虎,AKESO股票老虎国际,AKESO行情,AKESO股票行情,AKESO股价,AKESO股市,AKESO股票价格,AKESO股票交易,AKESO股票购买,AKESO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AKESO(09926) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}